Results 61 to 70 of about 247,387 (224)

(Not) Summing over Kaluza-Kleins

open access: yes, 2007
Models in extra-dimensions have unique features. Many of their surprising properties simply result from the underlying 5D structure. This structure shows up as ``Sum Rules'' involving the whole tower of Kaluza-Kleins.
Hirn, Johannes, Sanz, Veronica
core   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

The Mixed Partition Dimension: A New Resolvability Parameter in Graph Theory

open access: yesIEEE Access
In this article, we introduce a novel graph-theoretical parameter called the mixed partition dimension and apply it to the path graph and the hexagonal network.
Siti Norziahidayu Amzee Zamri   +4 more
doaj   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

open access: yesMolecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff   +11 more
wiley   +1 more source

Bures volume of the set of mixed quantum states

open access: yes, 2005
We compute the volume of the N^2-1 dimensional set M_N of density matrices of size N with respect to the Bures measure and show that it is equal to that of a N^2-1 dimensional hyper-halfsphere of radius 1/2.
Bhattacharyya A   +41 more
core   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Strong Coupling Dynamics of the Higgs Branch: Rolling a Higgs by Collapsing an Instanton

open access: yes, 2004
We construct the dual supergravity description of strongly coupled, large $N$, eight-supercharge gauge theories with fundamental hypermultiplets at points on the mixed Coulomb-Higgs branch.
Aharony   +39 more
core   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

open access: yesMolecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung   +17 more
wiley   +1 more source

Double Trace Interfaces

open access: yes, 2017
We introduce and study renormalization group interfaces between two holographic conformal theories which are related by deformation by a scalar double trace operator.
Melby-Thompson, Charles   +1 more
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy